The Delaware judge's ruling is a blow to the pharmaceutical industry, which had never been required to negotiate prices with regulators in the U.S. prior to the IRA's enactment.
Pharma companies had until March 2 to respond to the Biden administration's opening bid for fair prices for drugs, which include AstraZeneca's Farxiga, a therapy for diabetes, chronic kidney disease, and heart failure.
#astrazeneca #prescription-drug-price-negotiations #medicare-part-d #2022-inflation-reduction-act #federal-court-ruling
[
add
]
[
|
|
...
]